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Cooperative STAT/NF-κB signaling regulates
lymphoma metabolic reprogramming and aberrant
GOT2 expression
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Knowledge of stromal factors that have a role in the transcriptional regulation of metabolic
pathways aside from c-Myc is fundamental to improvements in lymphoma therapy. Using a
MYC-inducible human B-cell line, we observed the cooperative activation of STAT3 and NF-
κB by IL10 and CpG stimulation. We show that IL10+ CpG-mediated cell proliferation of
MYClow cells depends on glutaminolysis. By 13C- and 15N-tracing of glutamine metabolism
and metabolite rescue experiments, we demonstrate that GOT2 provides aspartate and
nucleotides to cells with activated or aberrant Jak/STAT and NF-κB signaling. A model of
GOT2 transcriptional regulation is proposed, in which the cooperative phosphorylation of
STAT3 and direct joint binding of STAT3 and p65/NF-κB to the proximal GOT2 promoter are
important. Furthermore, high aberrant GOT2 expression is prognostic in diffuse large B-cell
lymphoma underscoring the current ﬁndings and importance of stromal factors in lymphoma
biology.
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There is growing evidence for a cooperative role of stromalfactors in the shift from quiescence to the proliferation andtransformation of lymphocytes1–3. A fundamental ques-
tion is how microenvironmental factors and the intracellular
processes activated by them regulate metabolic reprogramming.
Further, a deeper understanding of the differences between pro-
cesses activated by either stromal or well-known single or com-
plex genetic drivers such as the proto-oncogene c-MYC (MYC) is
crucial to the development of novel targeted cancer therapies.
MYC has been shown to increase glutaminolysis and glycolysis
to support tumor cell proliferation4. A central role of glutami-
nolysis in resting and proliferating B-cells was shown for the
MYC-inducible human B-cell line P493-6, which serves as a
model of MYC-driven lymphoma or normal B-cells5. In this
model, MYC drives glutamine (Gln) catabolism via the aberrant
expression of glutaminase (GLS). Upregulation of GLS increases
the conversion of Gln to glutamate (Glu), which can be further
metabolized to α-ketoglutarate (α-KG)6–8. The latter is a key
metabolite involved in energy production via the tricarboxylic
acid cycle (TCA) and it is also used as a biosynthetic precursor.
Notably, α-KG may be synthesized from Glu by two different
mechanisms: deamination by glutamate dehydrogenases
(GLUD1/2) or transamination by aspartate transaminases
(GOT1/2) or alanine transaminases (GPT1/2). The latter also
generate additional non-essential amino acids from Gln and are
known to be regulated by MYC9,10.
Recently, we have shown distinct changes in global gene
expression (GE) induced by stromal stimuli that activate pattern
recognition receptors and thereby mediate signaling in B-cells11.
We further identiﬁed a combination of factors of the B-cell and
lymphoma microenvironment that are capable of promoting
proliferation in MYC-deprived P493-6 cells through signal
transducer and activator of transcription (STAT) 3 and nuclear
factor-κB (NF-κB) comparable to MYC overexpression12. Two
questions emerging from these studies are whether cell pro-
liferation in this model B-cell line is accompanied by metabolic
reprogramming and whether such reprogramming is different or
similar to that induced by MYC. Furthermore, it is important to
understand how metabolic GE is regulated in the absence of
aberrant MYC. This is necessary, as aberrant STAT and NF-κB
signaling networks have been described among others in diffuse
large B-cell lymphoma (DLBCL) and Hodgkin’s lymphoma (HL)
(reviewed by refs. 13,14). A signiﬁcant proportion of patients with
DLBCL do not respond fully to the standard immunochem-
otherapy. This indicates a critical need for a better understanding
of the speciﬁc pathways perturbed. Interestingly, a ﬁrst metabolic
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Fig. 1 Activation of cell metabolism and global gene expression by combined stimulation of P493-6 cells with IL10 and CpG. a Heat map of changes in
intracellular metabolite concentrations depicted as Log2FC after IL10 and/or CpG stimulation of P493-6 MYClow cells in relation to unstimulated cells.
Heat map of gene expression changes associated with b glycolysis (KEGG-term) and c glutaminolysis (KEGG-term), respectively, after IL10 and/or CpG
stimulation of P493-6 MYClow cells presented as Log2FC. Mean of three independent experiments is shown in all heat maps. Effects on gene expression
were analyzed by linear regression and p-values for the IL10:CpG interaction terms were calculated (adjusted by Benjamini–Hochberg). Positive synergistic
interactions are marked with a star (*p < 0.05). Relative cell counts of d IL10+CpG-stimulated P493-6 MYClow cells and e unstimulated P493-6 MYChigh
cells grown in media with and without either glucose (–Glc) or glutamine (–Gln). Mean ± SD of three independent experiments are given
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distinction between DLBCL subtypes and a model for HL cells
was provided15,16. However, the precise network of factors reg-
ulating the different metabolic subtypes remains unclear. It is also
uncertain how the microenvironment in lymphomas may be
involved in metabolic reprogramming and whether glutamino-
lysis in this context is similar to MYC-dependent lymphoma17,18.
Inhibition of glutaminolysis is considered a promising therapeutic
option in various cancers19. It is therefore vital to understand its
role and mechanism of deregulation in lymphomas.
Here we hypothesize, that Gln metabolism is important for
lymphoma proliferation and regulated by a combination of
intracellular signaling pathways such as STAT3 and NF-κB, either
activated by factors of the microenvironment or intrinsic genetic
lesions. To investigate this, an integrative analysis of tran-
scriptomic, metabolomic, and clinical data was conducted, to
identify and delineate metabolic processes and the regulation of
genes involved in glutaminolysis that may support B-cell pro-
liferation and transformation speciﬁcally.
Results
Metabolic adaptation by IL10 and CpG in MYC-deprived B-
cells. Various studies have revealed that the adaptation of meta-
bolic processes is essential to sustained proliferation. We recently
analyzed the capacity of different B-cell-stimulating factors to
induce proliferation in MYC-deprived cells12. To evaluate the
speciﬁc changes in metabolism and global GE induced by these
factors, P493-6 cells were treated with either CD40L, CpG, αIgM
(BCR crosslink), IGF1, interleukin (IL)10, or various dual com-
binations thereof for 24 h. Linear regression analysis revealed that
the activation of MYC-deprived P493-6 (MYClow) cells by a
combination of IL10 and CpG was associated with synergistic
changes in cell metabolism and global activation of GE (Fig. 1 and
Supplementary Fig. 1). Given this synergy and our recent
observation that IL10R and Toll-like receptor (TLR) 9 drive cell
proliferation through the activation of STAT3 and NF-κB sig-
naling, we focused our investigation on the activation of these
signaling pathways13. The corresponding changes in intracellular
metabolites and related genes in IL10-, CpG-, and IL10+CpG-
stimulated MYClow cells are presented in Fig. 1. The intracellular
amounts of TCA cycle intermediates and amino acids are strongly
increased by IL10+ CpG co-stimulation compared with MYClow
cells exposed to either or no stimulus (Fig. 1a). These metabolic
changes were accompanied by a marked increase in the expres-
sion of genes involved in glutaminolysis and glycolysis (Fig. 1b,c).
Importantly, total cellular protein amounts were also increased
(Supplementary Data 1). Interestingly, IL10+ CpG co-
stimulation of MYClow cells resulted in increased cell size simi-
lar to that of MYChigh cells (Supplementary Fig. 2).
Next, we measured both uptake of Gln and glucose (Glc), and
secretion of lactate to determine the lactate-to-glucose molar ratio
(Lac/Glc) (Supplementary Fig. 3). Strikingly, the uptake of both
Gln and Glc was signiﬁcantly increased in IL10+CpG-
stimulated MYClow cells compared with cells exposed to either
or no stimulus and even more so in MYChigh cells (Supplemen-
tary Fig. 3a, b). The Lac/Glc ratio was similar across the
conditions analyzed and indicated that Glc is predominantly
converted to lactate as reported before (Supplementary Figure 3c)
20. However, compared with MYChigh cells, both Glc consump-
tion and lactate production are lower in IL10+ CpG-stimulated
MYClow cells.
To test whether increased glycolysis and/or glutaminolysis
induced by IL10R and TLR9 signaling was necessary to support
B-cell proliferation, we cultured P493-6 cells in the presence or
absence of Gln or Glc. Cell doubling was monitored over 3 days.
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Fig. 2 Proliferation of IL10+CpG-stimulated and MYC-overexpressing cells is dependent on different glutamine-derived metabolites. a Mean isotopic
enrichment of metabolites in unstimulated and IL10+ CpG-stimulated P493-6 MYClow, as well as unstimulated P493-6 MYChigh cells treated with 13C5-
glutamine within the text only 13C5-Gln is used?. b Scheme of oxidative decarboxylation (blue) and reductive carboxylation (red). Both can be
distinguished by isotopic labelling in mass spectrometry. c Isotopic fractions of citrate in IL10+ CpG-stimulated P493-6 MYClow and P493-6 MYChigh
cells. Mass spectra were analysed according to the different masses of citrate. Data on 1-13C-glutamine within the main text 1-13C-Gln is used ? labeling are
summarized in Supplementary Fig. 5. Fractions of d m+ 1 15N isotopologue in selected amino acids and e 15N-enriched nucleobases in unstimulated and
IL10+ CpG-stimulated P493-6 MYClow, as well as P493-6 MYChigh cells. f,g Relative cell counts of IL10+ CpG-stimulated P493-6 MYClow and P493-6
MYChigh cells grown in Gln-deprived and metabolite-treated media. Cells were treated with either f TCA metabolites (Pyr= pyruvate, α-KG= dimethyl 2-
oxoglutarate, Mal= diethyl malate, OAA= oxaloacetate) or g aspartate (Asp) and nucleobases (A= adenine, T= thymine) for 24 h. For all plots, error
bars represent mean ± SD of three independent experiments and results from Bonferroni post hoc tests on a one-way ANOVA results are given (*p < 0.05,
**p < 0.01, ***p < 0.001)
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In media containing both Glc and Gln, the proliferation of IL10
+CpG-stimulated MYClow cells was comparable to that of
MYChigh cells (Fig. 1d,e). Withdrawal of Gln strongly reduced cell
doubling in both IL10+ CpG-stimulated MYClow and MYChigh
cells, whereas the effect of Glc removal was less pronounced
(Fig. 1d,e). Notably, neither unstimulated nor singly stimulated
MYClow cells proliferated under the experimental conditions used
(Supplementary Fig. 4).
In conclusion, stimulation of P493-6 MYClow cells with IL10+
CpG resulted in global metabolic reprogramming, with Gln being
essential for sustaining proliferation.
Anabolic processes of glutaminolysis in B-cell proliferation. To
further explore the role of Gln in the proliferation of IL10+CpG-
stimulated MYClow cells, we performed 13C-Gln tracing experi-
ments. Cells were cultured in the presence of 13C5-Gln for 24 h,
the fractional abundance of 13C-isotopologues of selected meta-
bolites was measured and the isotopic enrichment calculated
(Fig. 2a). In comparison with unstimulated MYClow cells, IL10+
CpG-stimulated MYClow cells were signiﬁcantly enriched with
13C-labelled TCA cycle intermediates, thus corroborating the
importance of Gln as an anabolic precursor. A comparable
inclusion of labelled carbons into the TCA cycle was observed in
MYChigh cells, consistent with previously published data on the
P493-6 cell line8. More importantly, we observed increased
incorporation of Gln-derived carbons into the amino acids
aspartic acid (Asp), glutamic acid (Glu), proline (Pro), and the
non-proteinogenic amino acid ornithine, but not into other
amino acids analysed (e.g., alanine, glycine, and serine) (Fig. 2a).
Hence, IL10+ CpG-stimulated B-cells utilize Gln-derived car-
bons comparable to B-cells aberrantly expressing MYC. However,
the fractional abundance of m+ 4 citrate indicates that IL10+
CpG-stimulated cells use less Gln for oxidative phosphorylation
than MYChigh cells, whereas reductive carboxylation of Gln-
derived α-KG to citrate (m+ 5 citrate) seems to be equally pre-
sent in both IL10+ CpG-stimulated MYClow and MYChigh cells
(Fig. 2b,c). To further support our conclusion on reductive car-
boxylation, cells were labeled with 1-13C-Gln for 24 h. Measure-
ment of the m+ 1 citrate 13C-istotopologue fraction revealed that
IL10+CpG-stimulated MYClow cells contained a higher fraction
of m+ 1 citrate than unstimulated cells (9.7% vs. 5.4%)
(Supplementary Fig. 5a, b). In comparison, the respective fraction
of m+ 1 citrate in MYChigh cells was 12% (Supplementary
Fig. 5a, b).
To gain further insight into Gln catabolism in IL10+CpG-
stimulated MYClow cells, ɑ-15N-Gln tracing studies were
performed (Fig. 2d). The amino acids Ala, Asp, Glu, and Pro
showed increased enrichment of 15N in IL10+ CpG-stimulated
MYClow cells. Even stronger was the incorporation in MYChigh
cells. Importantly, labeled nitrogen derived from Asp and Gly was
also observed in nucleobases (m+ 1, m+ 2) (Fig. 2e). The very
low levels of nitrogen incorporation in the letter can be explained
by the used tracer, where only the nitrogen in ɑ-position of Gln
was labeled to assess the contribution to nucleobase biosynthesis.
In summary, B-cell proliferation induced by the co-stimulation
with IL10 and CpG relies on glutaminolysis and Gln-dependent
anabolic processes.
Glutaminolysis supports anabolic functions after IL10+CpG.
To further evaluate which of the Gln-derived metabolites are
essential for cell proliferation, we added various metabolites to
Gln-starved IL10+ CpG-stimulated MYClow and unstimulated
MYChigh cells, respectively, and evaluated their capacity to restore
cell doubling (Fig. 2f). Of the TCA-derived metabolites tested
(malate, oxaloacetate (OAA), α-KG, and pyruvate (Pyr)), only
OAA restored the proliferation of IL10+CpG-stimulated cells
signiﬁcantly. In contrast, the proliferation of MYChigh cells was
restored in part by Pyr and, to a much greater extent, by the
addition of dimethyl α-KG, a cell-permeating form of α-KG
(Fig. 2f).
The TCA cycle intermediate OAA provides the carbon skeleton
for the production of aspartate in a glutamate-dependent reaction
catalyzed by the aminotransferase GOT2. Hence, next we tested
whether supraphysiological levels of Asp were also able to restore
cell proliferation following Gln deprivation. Indeed, Asp restored
the proliferation of Gln-starved IL10+CpG-stimulated cells, but
surprisingly not of Gln-deprived MYChigh cells (Fig. 2g). As Asp
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Fig. 3 Proliferation of P493-6 and B-cell lymphoma cells requires
transaminase activity. a Inhibition of cell doubling of IL10+ CpG-stimulated
P493-6 MYClow and P493-6 MYChigh cells after 24 h of treatment with CB-
839 or AOA. b Inhibition of cell doubling of the B-cell lymphoma cell lines
CA-46, OCI-Ly3, and L-428 using CB-839 or AOA treatment for 24 h. c
Intracellular amino acid abundance in IL10+ CpG-stimulated MYClow and
MYChigh cells 24 h after AOA treatment and stimulation. For each amino
acid data were normalized relative to the corresponding values of DMSO-
treated cells. For all plots, error bars represent mean ± SD of three
independent experiments and results from Bonferroni post hoc tests on a
one-way ANOVA are given (*p < 0.05, **p < 0.01, ***p < 0.001)
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is an important precursor in nucleotide biosynthesis, we further
investigated the capacity of nucleobases to restore cell prolifera-
tion. Addition of the nucleobases adenine (A) or thymine (T) led
to the almost complete restoration of IL10+CpG-induced
MYClow cell proliferation (Fig. 2g). As demonstrated for Asp,
the nucleobases adenine or thymine also proved unable to
overcome the Gln deﬁciency in MYChigh cells in culture medium.
This indicates that Gln is essential for nucleotide biosynthesis in
IL10+ CpG-stimulated cell proliferation and suggests that IL10
and CpG together reprogram glutaminolysis of resting B-cells
toward anabolic metabolism to support Asp and nucleobase
synthesis, and thus cell proliferation.
As OAA, Pyr, and α-KG are capable of replenishing the TCA
cycle, which provides succinate and reducing equivalents to
oxidative phosphorylation, we compared the oxygen consump-
tion (OCR) and extracellular acidiﬁcation rates (ECAR) in the
presence or absence of Gln (Supplementary Figure 6a, b). In IL10
+CpG-stimulated MYClow cells the OCR and ECAR were higher
than in unstimulated MYClow cells but remained unchanged in
the absence of Gln. In contrast, the OCR and ECAR rates of
MYChigh cells were reduced signiﬁcantly to the level of
unstimulated MYClow cells upon Gln withdrawal. It is therefore
reasonable to argue that IL10+CpG-stimulated MYClow cells use
substrates other than Gln to support respiration, whereas Gln is
necessary to maintain OCR in MYChigh cells. This is consistent
with the above observation that IL10+ CpG-stimulated MYClow
cells use less Gln for oxidative phosphorylation than MYChigh
cells (Fig. 2). In addition, OCR was measured after the respective
inhibition of the mitochondrial pyruvate carrier (MPC1) by
UK5099, carnitine palmitoyltransferase (CPT1), a key regulator
of the β-oxidation of long-chain fatty acids, by etomoxir, and
glutaminolysis by the GLS inhibitor Bis-2-(5-phenylacetamido-
1,3,4-thiadiazol-2-yl)ethyl sulﬁde (BPTES) (Supplementary
Fig. 6c). As expected, BPTES affected MYChigh cells much more
than IL10+CpG-stimulated MYClow cells. MYClow and IL10+
CpG-stimulated MYClow cells consumed less amounts of fatty
acids than MYChigh cells. Furthermore, in contrast to both
unstimulated MYClow and MYChigh cells, oxidative phosphoryla-
tion in IL10+ CpG-stimulated cells was almost independent of
Glc.
Thus, our data suggest that IL10+ CpG-stimulated B-cells are
characterized by glutaminolysis supporting anabolic functions,
and oxidative phosphorylation is supported by both fatty acids
and Gln.
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Fig. 4 GOT2 supports the proliferation of IL10+ CpG-stimulated and MYC-overexpressing cells. a Transient knockdown of GOT1 and GOT2 in P493-6 cells
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Transaminases in IL10+CpG-mediated metabolic repro-
gramming. Glutaminolysis and cancer cell proliferation have
been targeted in various studies6,8,21. The importance of the
aspartate aminotransferases GOT1 and GOT2 in the generation
of Glu and Asp from α-KG and OAA, respectively, prompted us
to study whether their inhibition may suppress cell proliferation
as readily as the inhibition of GLS. As shown above, both Asp and
α-KG restored cell proliferation in a context dependent manner.
This implies different, context-dependent roles of transaminases
in glutaminolysis and B-cell proliferation. We therefore compared
the effects of Gln deprivation, GLS inhibition, and transaminase
inhibition on proliferation of IL10+ CpG-stimulated MYClow
and unstimulated MYChigh cells. Inhibitors such as CB-839 for
GLS or aminooxyacetate (AOA) for transaminases were used for
this purpose. AOA is a general inhibitor of pyridoxal phosphate-
dependent enzymes, including transaminases, which are involved
in amino acid metabolism. Furthermore, it displayed signiﬁcant
antitumoral effects in preclinical studies9. Treatment of cells with
CB-839 or AOA for 24 h caused a strong reduction in cell pro-
liferation in both IL10+ CpG-stimulated MYClow and unstimu-
lated MYChigh cells (Fig. 3a). The observed decrease was
comparable to that caused by Gln starvation. Similar effects were
also observed for lymphoma cell lines representative of aberrant
MYC activity (CA-46) or constitutive Jak/STAT and NF-kB
pathway activation (OCI-Ly3, L-428) (Fig. 3b). The similar effects
of Gln deprivation and AOA treatment were also demonstrated
for the additional B-cell lines BJAB, TMD-8, HBL-1, and KM-H2,
thus underscoring the importance of transaminases in sustaining
B-cell lymphoma proliferation (Supplementary Fig. 7b).
Importantly, measurements of intracellular amino acid
amounts revealed that Asp levels dropped signiﬁcantly after
AOA treatment in both IL10+ CpG-stimulated MYClow and
unstimulated MYChigh cells (Fig. 3c). The intracellular levels of
other amino acids such as Glu, Gly, Pro, or Ser were only slightly
affected by transaminase inhibition. Notably, Ala levels were only
signiﬁcantly affected after AOA treatment in MYChigh cells
(Fig. 3c).
To explore whether the loss of Asp and nucleotide biosynthesis
can explain the proliferation block by AOA treatment, we
performed again proliferation restoration experiments
(Supplementary Fig. 8a, b). Consistent with the results for Gln
deprivation, the proliferation of IL10+CpG-stimulated MYClow
cells was restored signiﬁcantly by Asp or nucleobase addition
following AOA treatment. The same held true for OCI-Ly3 and
L-428 cells. Furthermore, only a marginal but insigniﬁcant
increase in MYChigh cell proliferation was observed after Asp or
nucleobase supplementation in line with the effects of Gln
deprivation and this was also observed in CA-46 cells. Using
13C5-Gln as a tracer, glutaminolysis was further characterized in
the lymphoma cell lines OCI-Ly3, L-428, and CA-46. Cells were
labeled with 13C5-Gln for 24 h and the fractional abundance of
13C isotopologs of citrate was determined (Supplementary Fig. 5c).
As for the P493-6 cells, the m+ 4 isotopolog was the most
abundant in CA-46 and OCI-Ly3 cells. In L-428 cells, in contrast,
the m+ 5 isotopolog dominated.
To further elucidate the impact of this transaminase inhibition
on energy production, we measured the OCR and ECAR
following AOA treatment in P493-6 cells. The cells were seeded
in Gln-depleted media, and Gln and AOA were added
consecutively. OCR was monitored continuously (Supplementary
Fig. 8c, d). In the absence of Gln, IL10+CpG-stimulated cells
displayed greater OCR than MYChigh cells. Addition of Gln
increased the OCR of MYChigh cells but not of IL10+CpG-
stimulated MYClow cells. Importantly, this effect was reversed by
AOA treatment. However, the OCR of IL10+ CpG-stimulated
MYClow cells remained unaffected by AOA treatment.
In conclusion, transamination is critical in sustaining prolif-
eration in both IL10+ CpG-stimulated MYClow and unstimu-
lated MYChigh cells. However, the former, unlike MYChigh cells,
are not dependent on transamination for oxidative
phosphorylation.
GOT2 in IL10+CpG-stimulated MYClow and MYChigh cells.
The transaminase GOT2 catalyzes the conversion of Glu and
OAA to α-KG and Asp, whereas GOT1 catalyzes the reverse
reaction in the malate–aspartate shuttle as long as the mito-
chondrial electron transport chain is functional19,21–23.
The abundance and catalytic activity of GOTs is increased after
IL10+CpG stimulation of MYClow cells as shown in Supple-
mentary Data 1 and Supplementary Fig. 9. Thus, the
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transcriptional activation (Fig. 1c) is also translated into protein
and enzymatic activity.
To investigate whether GOT1 and GOT2 are involved in the
Gln-dependent proliferation of B-cells, we performed RNA
interference (RNAi)-mediated knockdowns of both the cytosolic
GOT1 and the mitochondrial GOT2 in P493-6 cells (Fig. 4a). A
knockdown of about 60%–70% was achieved for both. The
achieved knockdown of GOT2 was sufﬁcient to cause a reduction
in cell proliferation of both IL10+ CpG-stimulated MYClow and
unstimulated MYChigh cells. The GOT1 knockdown, on the other
hand, had no discernible effect on the proliferation of IL10+
CpG-stimulated MYClow cells, whereas proliferation in MYChigh
cells decreased to the same extent as seen with the GOT2
knockdown (Fig. 4b).
To investigate the capacity of Asp or α-KG to restore reduced
cell proliferation after GOT2 knockdown, cells were grown in
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normal medium and cell proliferation was analyzed after addition
of α-KG, Asp, or nucleobases. Importantly, the addition of
adenine and thymine fully restored the proliferation of IL10+
CpG-stimulated MYClow cells, while Asp restored it partially
(Fig. 4c). In contrast, MYChigh cell proliferation could only be
restored upon addition of α-KG (Fig. 4d). Differences between the
effects of AOA treatment and GOT2 knockdown indicated the
involvement of other transaminases. This prompted us to
investigate the glutamate pyruvate transaminase (GPT2), the
GE of which had increased less in IL10+ CpG-stimulated
MYClow cells compared with that in MYChigh cells. No signiﬁcant
decrease in cell proliferation was observed after GPT2 knockdown
in IL10+ CpG stimulated MYClow cells. In contrast, cell
proliferation of MYChigh cells was decreased after GPT2
knockdown (Fig. 4e/f). A speciﬁc role for GPT2 in MYChigh
cells is in line with the above described higher nitrogen
incorporation into Ala and the decrease in Ala abundance after
AOA treatment and the recent description of cells with
cooperating oncogenic mutations24.
In order to gain insight into the role of GOT2 in B-cell
lymphoma, OCI-Ly3, L-428, and CA-46 cells were selected.
Reasonable GOT2 knockdown was achieved in all three cell lines
(Fig. 5a). Knockdown of GOT2 signiﬁcantly decreased the
proliferation of all cell lines (Fig. 5a,b). However, as in IL10+
CpG-stimulated P493-6 MYClow cells, the reduced cell prolifera-
tion was almost completely restored by Asp or nucleobases. In
contrast, the reduced proliferation of CA-46 cells following GOT2
knockdown was restored only by the addition of α-KG but not by
b
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Asp or nucleobases. It thus appears that glutaminolysis and cell
proliferation in CA-46 cells depend on GOT2, as observed in
P493-6 MYChigh cells.
In summary, we propose a model in which GOT2 is a
metabolic hub in B-cells in a context-dependent manner,
providing the cells with either Asp for biosynthesis or α-KG for
energy demands.
GOT2 expression is regulated by a combination of STAT3/NF-
κB. Previously, we demonstrated that IL10 and CpG activate
STAT3 and NF-κB signaling in P493-6 cells and cause a syner-
gistic increase in the expression of the cell cycle regulator CDK4
through direct, simultaneous binding to its gene promoter12. To
address the question, whether IL10+ CpG stimulation also
increases the expression of GOT2 in a NF-κB and/or STAT3-
dependent manner, we treated MYClow cells with the IKK inhi-
bitor ACHP and the JAK inhibitor Ruxolitinib before stimulation
with IL10, CpG, or IL10+ CpG (Fig. 6a). Ruxolitinib treatment
decreased GOT2 expression in IL10+ CpG-stimulated cells
comparable to that observed in cells stimulated with CpG only. In
contrast, ACHP treatment completely abrogated the increase in
GOT2 expression after any stimulation. Notably, the increase in
GOT2 expression in MYChigh cells was not affected by any of the
inhibitors (Fig. 6a).
For further validation, we performed RNAi-mediated STAT3
and RELA (p65) knockdowns in MYClow cells before IL10 and
CpG stimulation (Fig. 6b). Consistent with the inhibitor
treatments, both STAT3 and RELA knockdowns resulted in a
strong reduction in GOT2 expression in IL10+ CpG-stimulated
MYClow cells (Fig. 6c). Furthermore, a direct regulatory function
of STAT3 and p65 in GOT2 expression was observed by
corresponding chromatin immunoprecipitation (ChIP) (Fig. 6d).
In MYClow cells stimulated with IL10 or CpG, we observed an
increase in the binding of STAT3 or p65/NF-κB to the proximal
promoter of GOT2. However, transcription factor binding exerted
little effect on gene transcription. Importantly, following IL10+
CpG-co-stimulation, strong joint binding of STAT3 and p65 to
the same promoter region was observed. This resulted in marked
GOT2 expression. This is the ﬁrst ever demonstration that GOT2
is a direct target of STAT3 and p65 NF-κB.
In addition, analysis of STAT3 phosphorylation in MYClow
cells showed that IL10 and CpG mediated the respective
phosphorylation of Tyr-705 and Ser-727 (Fig. 6e). Hence, both
coordinated STAT3 phosphorylation, which is a known pre-
requisite for the interaction of STAT3 with p65, and the joint
binding of STAT3 and p65 NF-κB to their target genes
mechanistically support the synergy of IL10 and CpG (Fig. 6e)25.
To exclude that increased cell proliferation of IL10+ CpG
stimulated MYClow cells was rather the result of increased MYC
expression mediated by STAT3 and p65 activation, both changes
in Myc protein abundance and the effect of RNAi-mediated Myc
knockdown onto cell proliferation were monitored over 24 h
(Supplementary Fig. 10). A transient low activation of Myc was
observed after both CpG and IL10+ CpG stimulation of MYClow
cells. However, cell proliferation was only increased upon IL10+
CpG costimulation (Supplementary Fig. 10a). Furthermore, the
knockdown of Myc affected the proliferation of MYChigh cells
much stronger, despite a less pronounced reduction in Myc
(Supplementary Figure 10b, c). Considering STAT3/p65 ChIP
analysis, Jak/STAT and NF-κB inhibition, and Myc knockdown
data, we conclude that the synergistic effect of IL10 and CpG is
driven mainly by STAT3 and NF-κB and not by Myc.
To test whether GOT2 expression depends on STAT3 and NF-
κB in other cell lines as well, OCI-Ly3 and TMD-8 lymphoma
cells were compared with BJAB and CA-46 cells, which do not
depend on STAT3/NF-κB (Supplementary Figure 7a). OCI-Ly3
and TMD-8 cells were derived from DLBCL and display
constitutively active STAT3 and NF-κB signaling due to
constitutively active TLR signaling and autocrine cytokine
production26. A signiﬁcant reduction in GOT2 expression was
observed on treating OCI-Ly3 and TMD-8 cell lines with
Ruxolitinib and ACHP (Fig. 6f).
It is thus reasonable to suggest that a general mechanism of
GOT2 expression has been identiﬁed which relies on combined
Jak/STAT and NF-κB signaling activity. Furthermore, our data
support a model in which the simultaneous activity of STAT3 and
NF-κB may substitute for the transcriptional activity of aberrant
MYC expression in regulating GOT2 expression and, conse-
quently, B-cell glutaminolysis and proliferation.
Aberrant GOT2 expression in lymphoma subtypes is prog-
nostic. Next we compared GOT2 GE between normal B-cell
controls (naive pre-germinal B-cells, B lymphocytes, centroblasts,
and memory B-cells) and different B-cell lymphomas (BL,
DLBCL, chronic lymphocytic leukemia (CLL) and mantle cell
lymphoma (MCL)). Among controls, GOT2 GE was highest in
proliferating centroblasts. Even higher GOT2 expression was
found in DLBCL (p= 7.60E – 7, n= 32) and BL (p= 4.94E – 9, n
= 17) samples, but not in CLL and MCL in relation to normal B-
cell subsets (Fig. 7a). Nearly all BL cases (14/17) expressed greater
levels of GOT2 than centroblasts, whereas 14/32 DLBCL cases
demonstrated increased expression of GOT2 (Supplementary
Figure 11a, b). Importantly, no signiﬁcant differences in GE were
observed for GLS1, GLS2, GLUD1, GLUD2, GOT1, and GPT1 in
this dataset (Supplementary Figure 11c-h). We therefore conclude
that GOT2 is expressed aberrantly in a subset of lymphoma and is
characteristic of BL and a subgroup of DLBCL.
Next, GOT2 was analysed using immunohistochemistry
(Table 1, Fig. 7b, and Supplementary Fig. 12). We observed that
liver samples were positively stained for GOT2, whereas other
tested tissues (muscle, skin, and lung) were negative. Inside the
lymph nodes, normal lymphocytes are usually not stained with
Table 1 Immunohistochemical analysis of GOT2 distribution in B-cell lymphoma
Number of cases Positive Partial positive
Hodgkin lymphoma 15 15 0
Diffuse large B-cell lympoma 10 8 2
Burkitt lymphoma 6 6 0
Mediastinal B-cell lymphoma 4 4 0
Acute B-cell leukemia 5 2 3
Partially positive (≤ 50% of lymphoma cells are stained with anti-GOT2 antibody) and positive ( > 50% of lymphoma cells are positive for GOT2). For additional details, see also Fig. 7B and Suppl.
Material and Methods section.
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anti-GOT2 antibodies, except for a few cells in the germinal
center (Fig. 7b, tonsil). Lymphoma tissues of HL, DLBCL, and BL
patients, in contrast, stained strongly for GOT2 thus supporting
the GE data (Fig. 7a, b).
To evaluate whether aberrant GOT2 GE affects overall survival,
we analysed a cohort of 157 DLBCL patient that had been treated
with immunochemotherapy (R-CHOP (Rituximab, Cyclopho-
sphamide, Hydroxydaunomycin, Oncovin, Prednisone))17. The
Kaplan–Meier plot demonstrates that high aberrant GOT2
expression is signiﬁcantly associated with a shorter overall
survival (p= 0.003) (Fig. 7c). The inclusion of GOT2 expression
in a Cox proportional hazards model, comprising in addition the
age, the international prognostic index (IPI), and the molecular
classiﬁcation as activated B-cell (ABC)-like DLBCL revealed an
enhanced relative risk in patients with high GOT2 expression
(hazard ratio: 2.28; p= 0.03756) (Supplementary Table 1)13. This
indicates that high GOT2 expression is an independent
prognostic factor.
Discussion
A combination of techniques has been used to study the effects of
the B-cell-stimulating factors IL10 and CpG on metabolism and
proliferation of MYC-deprived B-cells. Our analysis demonstrates
an important role of glutaminolysis and, in particular, GOT2 in
B-cells and subtypes of B-cell lymphoma. Importantly, the
metabolic responses are mediated by coordinated STAT3 and
p65/NF-κB activity. Furthermore, in STAT3/NF-κB-mediated
responses, Gln is utilized for Asp and nucleotide synthesis to
support B-cell proliferation. Thus, STAT3/p65-dependent upre-
gulation of GOT2 is a hitherto undescribed mechanism in the
mediation of glutaminolysis during lymphocyte proliferation and
transformation, albeit additional aminotransferases may be
involved in the B-cell model cell line studied.
In line with our view on the cooperation of microenviron-
mental factors is the description of the costimulation of T-cells
via the T-cell receptor and CD28 to support metabolic repro-
gramming and proliferation27,28. An important role for Glc
metabolism during lymphocyte activation has already been
demonstrated29. In previous studies, evidence was provided that
T-cell (or B-cell) receptor activation, TLR signaling, or IL-7 sti-
mulation increase Glc consumption in lymphocytes1,3,30. Inter-
estingly, full glycolytic responses rely mostly on AKT-associated
signaling pathway activities1,30. In contrast, glutaminolysis in
lymphocytes is regulated by either Myc- or CD28-mediated
activation of the ERK pathway2,31. The central role of glutami-
nolysis regulated by the combination of STAT/NF-κB, as
described here, thus extends our knowledge of metabolic net-
works in lymphocytes.
STAT3 alone has been described as a regulator of glycolysis
and the electron transport chain32. Furthermore, a role in the
metabolic shift toward Gln-dependent tumor growth, invasion,
and bioenergetics in ovarian cancer was observed33. In ErbB2-
positive breast cancer cells, NF-κB was found to upregulate GLS1,
thus acting as an oncogenic signal promoting Gln utilization34.
Our study reveals that in B-cells the combined action of STAT3/
p65 drives cell proliferation on a low MYC background com-
parable to aberrantMYC expression. Although to some extent the
cooperation of STAT3 and NF-κB signaling has already been
described in apoptosis, proliferation, and inﬂammation, our data
emphasizes the critical role of the cooperation of both tran-
scription factors in reprogramming glutaminolysis in B-cells.
STAT3 and p65 have already been shown to interact and
cooperate in regulating GE35,36. However, no canonical STAT3 or
NF-κB-binding sites within the proximal GOT2 promoter have
been described to date. We propose a model in which the dual
binding of NF-κB and STAT3 at the proximal GOT2 gene pro-
moter includes physical interaction as described for ICAM136.
Importantly, our study shows that STAT3 and p65 together bind
to sequences that differ from the canonical binding sites. In
addition, IL10 and CpG modulate STAT3 activity via phos-
phorylation of the amino acid residues Tyr-705 and Ser-727 in
STAT3. Therefore, it is reasonable to conclude that both coor-
dinated STAT3 phosphorylation and joint binding of STAT3 and
p65 NF-κB to their target genes are important in the observed
pathway synergy of these microenvironmental factors. Future
studies may reveal additional posttranslational modiﬁcations in
both STAT3 and p6525. We propose that STAT3/p65-regulated
GOT2 expression is an alternative regulatory circuit to Myc12,37.
However, other Myc-regulatory pathways for metabolic enzymes
have also been identiﬁed, such as MYC/micro-RNA-regulated
GLS expression or glutamine synthase promoter demethyla-
tion7,38. Future evaluation will be necessary to determine whether
additional indirect mechanism can be observed for STAT3/NF-
κB or whether both transcription factors are also involved in
super-enhancer regulation as demonstrated for Myc or might
have crosstalks with PI3K, 14-3-339–41.
The important role of Asp in B-cell metabolism and pro-
liferation detected maintains some parallels to recent studies.
There it was revealed that a crucial role of cellular respiration is to
maintain redox homeostasis to support Asp and therefore
nucleotide synthesis22,42. In addition, it was shown in glio-
blastoma that the conversion of Glu to Gln fuels de novo purine
biosynthesis43. Another study demonstrated that mammary epi-
thelial cells can switch from oxidative deamination of Glu to α-
KG catalyzed by GLUD to the conversion of OAA into Asp by
transamination of Gln catalyzed by GOTs44. In this scenario, cells
are provided with energy and amino acids simultaneously. The
different glutaminolysis networks identiﬁed herein in which IL10
+ CpG-stimulated MYClow cells use less Gln for oxidative
phosphorylation compared with MYChigh cells ﬁts well with
previous data demonstrating that MYC-dependent osteosarcoma
cells use Gln for cellular respiration10. Therefore, we propose that
GOT2 serves as a metabolic hub, providing cells with Asp and/or
α-KG for energy demands and biosynthetic processes such as
nucleotide biosynthesis in a context-dependent manner. Further,
transaminases other than GOT2 such as GPT2 may contribute to
the observed differences. GPT2 promotes Gln-dependent ana-
plerosis by catalyzing the reversible addition of an amino group
from glutamate to Pyr generating Ala and α-KG to fuel the TCA.
It is believed that this provides a link between glycolysis, gluta-
minolysis, and TCA anaplerosis. Smith et al.24 provided evidence
for a model in which GPT2 is critical for the cancer phenotype
including Gln-driven TCA anaplerosis and coupling of glycolytic
Pyr output to Gln catabolism24. Interestingly, GPT2 was dis-
pensable in not fully transformed cells similar as observed herein
for IL10+ CpG stimulated MYClow cells. Thus it seems to be
reasonable that the Warburg effect supports oncogenesis via
GPT2-mediated coupling of Pyr production to Gln catabolism in
MYChigh cells but not IL10+ CpG stimulated MYClow cells24. It
remains to be seen whether the observed oxidative decarboxyla-
tion of malate into Pyr also contributes to the observed differ-
ences between IL10+CpG-stimulated MYClow and MYChigh
cells20,45.
Furthermore, the context dependence of glutaminolysis was
also reﬂected in the observation that oxidative phosphorylation of
IL10+CpG-stimulated MYClow cells was nearly independent
from transaminase activity and Gln or fatty acids were not as
dominantly involved as in MYChigh cells. In contrast, MYChigh
cells are characterized by a strong dependence of oxidative
phosphorylation from aminotransferases as observed by AOA
treatment but also form fatty acids and Gln. The lower nitrogen
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incorporation in Ala in IL10+ CpG stimulated MYClow cells as
in MYChigh cells, a stronger decrease of Ala amounts in MYChigh
cells after AOA treatment and the effect of the GPT2 knockdown
onto cell proliferation suggest that MYChigh depend much more
on anaplerosis to meet their increased energy, biosynthesis, and
redox needs46,47. Whether the postulated Asp, ornithine, and
arginine circuit is important as in M2-macrophages needs to be
tested48,49.
Pharmacological inhibition of aminotransferases has been
suggested as a treatment strategy in MYC-overexpressing breast
cancers9. Remembering that high aberrant GOT2 is prognostic in
DLBCL, transaminase inhibition might also represent an attrac-
tive treatment target in lymphoma. It is noteworthy that a sub-
type of DLBCL has been described as being dependent on
cooperative STAT3 and NF-κB activation26. Furthermore, aber-
rant STAT3 and NF-κB activation, as well as aberrant MYC
expression, are associated with inferior overall survival in DLBCL
patients50–54. Although in some cases activation of these pathway
may be explained by mutations inside the corresponding signal-
ing cascades, a deregulated microenvironment might also be
involved in the absence of complex intrinsic genetic lesions or
high aberrant MYC.
Recently, the ﬁrst metabolic distinction in DLBCL subtypes
was described. OxPhos DLBCL cell lines were characterized by a
strong mitochondrial component and a greater glycolytic ﬂux
when compared with other DLBCL cell lines15. Nevertheless, the
precise network of factors regulating this or other metabolic
landscapes is unknown. We now have strong evidence that
STAT3/NF-κB activity driven by either a complex micro-
environment in lymphomas or intrinsic genetic lesions is
important in the metabolic reprogramming of cells different from
OxPhos DLBCL. In addition, the recently described shifted
OXPHOS-linked ATP synthesis in HL cells when compared with
germinal center B-cells has to be complemented now by a strong
glutaminolysis component16. We propose that Gln-derived Asp/
nucleobases are important to HL cells, and that reductive car-
boxylation is more important than in other lymphoma cells.
Aminotransferases facilitate amino acid-mediated TCA ana-
plerosis and are emerging as critical determinants of oncogenesis.
Recently, GOT1, GPT2, the branched-chain amino acid trans-
ferase 1, and phosphoserine aminotransferase 1 have been found
to be essential for tumorigenesis of pancreatic adenocarcinoma,
glioblastoma, and breast cancer, respectively, further supporting
not only the herein described context-dependent role of GOT2
but also of GOT1 and GPT221,24,55,56.
Our ﬁndings not only provide functional validation of meta-
bolic differences between different lymphoma subtypes. They also
indicate that glutaminolysis and, in particular, GOT2 is a bio-
marker. Whether targeting GOT2 and glutaminolysis or inhibit-
ing Jak/STAT and NF-κB signaling is more efﬁcient in
corresponding lymphoma subtypes needs to be investigated in
prospective preclinical and clinical studies. However, as targeting
MYC is still a challenge, targeting aminotransferases may prove
to be an attractive treatment strategy or add-on therapy option in
the future9,57.
Methods
Cell culture. P493-6 cells were a kind gift of Georg Bornkamm (Munich, Ger-
many). TMD-8 and HBL-1 cells were gifted by Daniel Krappmann (Munich,
Germany). All other cell lines (CA-46, BJAB, OCI-Ly3, KM-H2, and L-428) were
obtained from the DSMZ Germany. All cell lines were identiﬁed and checked for
cross contamination by Short Tandem Repeat (STR) proﬁling by the DSMZ
Germany. Cell lines were routinely checked for Mycoplasma contamination by
PCR using Venor-GeM Mycoplasma Detection Kit (Sigma-Aldrich, Munich,
Germany). All cell lines were cultured in RPMI 1640 (Lonza, Cologne, Germany)
containing 2 mM Gln supplemented with 10% GibcoTM FCS (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) and 1:100 penicillin/streptomycin (Thermo Fisher
Scientiﬁc) at 37 °C with 5% CO2. To repress MYC in P493-6, the cells were treated
with 1 ng/mL doxycycline for 24 h. Before the start of the stimulation experiments,
the cell culture media was replaced by fresh media with or without adding 1 ng/mL
doxycycline as indicated. The reduced expression ofMYC by doxycycline remained
reduced for up to 72 h.
For cell doubling experiments, P493-6 cells were stimulated every 24 h and cell
number was counted 48 h after the ﬁrst stimulation by using a hemocytometer and
Trypan blue staining. Other cell lines were treated as indicated and cell count
relative to the number of seeded cells was determined likewise after 48 h.
Stimulants, inhibitors, and metabolites used in this study are further described
in the Supplementary Information. Concentrations of stimuli, inhibitors and
metabolites used in this study are listed in Supplementary Table 2-4. For further
stimulations of P493-6 cells with IL10, CpG, and IL10+ CpG, full working
concentrations were used. It is noteworthy that after addition of metabolites, pH of
cell culture media was adjusted to pH 7 by adding 1M NaOH or 1M HCl.
To stimulate P493-6 cells for transcriptomic and metabolic analysis in
Supplementary Fig. 1, P493-6 cells were counted, centrifuged, and seeded in fresh
cell culture medium at a density of 1∙106 cells/mL. As depicted, cells were treated
with either a single stimulus or combinations of at least two different stimuli, which
could each take one of two different concentrations (see Supplementary Tables 2
and 5).
Small interfering RNAs (siRNAs) against GOT1, GOT2, GPT2, STAT3, RELA
(all Smartpools, Dharmacon, Lafayette, USA) and scrambled control (Scrb,
InvitrogenTM SilencerTMSelect Negative Control No. 1, Thermo Fisher Scientiﬁc)
were transfected into cells by electroporation using Amaxa® Nucleofector™ system
(Lonza) according to the user manual (analog to protocol for Ramos cells). . siRNA
sequences are listed in Supplementary Table 6. Cell line-speciﬁc modiﬁcations are
shown Supplementary Table 7. P493-6 cell line was transfected in MYChigh state
and doxycycline was added 3 h after transfection to generate MYClow cells. All
following experiments, including western blot analysis to analyze knockdown
efﬁciency, were performed 24 h after knockdown.
Real-time PCR analysis. In all GE analyses, cells were collected and spiked with
1:10 Drosophila S2 cells as an external spike-in control59. RNA and complementary
DNA was generated by NucleoSpin RNA kit (Machery-Nagel, Düren, Germany)
and SuperScript II Reverse Transcriptase (Thermo Fisher Scientiﬁc), respectively.
Following primer sequences were used: GOT2 fwd: 5′-GAG AAC AGC GAA GTC
TTG AAG AGT G-3′, GOT2 rev: 5′-CTG GCT CCG ATC CTT AAG GCT-3′;
ACT42A fwd: 5′-CTA AGC AGT AGT CGG GCT GG-3′, ACT42 rev: 5′-GTC
TGC AAT GGG TGT GTT CG-3′. Relative fold changes were calculated as 2–ΔΔCt
relative to Drosophila ACT42A and corresponding control cells12.
RNA sequencing. One million P493-6 cells were spiked with 100,000 Drosophila
melanogaster cells as external controls to normalize the GE data to the number of
sample cells59. Total RNA was isolated using NucleoSpin Kit (Machery-Nagel).
RNA sequencing (RNA-seq) libraries were prepared from 1 µg total RNA (con-
taining human and Drosophila RNA). Library preparation was performed with the
TruSeq RNA Sample Preparation Kit v2 (Illumina, San Diego, CA, USA). Libraries
were sequenced in single end mode for 100 cycles on an Illumina HiSeq 2000.
We concatenated the genomes of Homo sapiens (GRCh38) and D. melanogaster
(Ensembl BDGP5), and mapped all sequence libraries against this concatenated
genome using TopHat version 2.0.13, indicating an unstranded sequencing
protocol (library-type fr-unstranded) and default settings for the remaining
parameters as described before59.
Datasets were searched for ribosomal RNA reads by means of BioBloomtools
(http://www.bcgsc.ca/platform/bioinfo/software/biobloomtools) using a score of
0.25 and kmer length 50, which were then removed from the bam ﬁles with custom
code (between 1.5% and 3.4% of the reads). Next, RNA-seq read counts were
assigned to Ensembl gene identiﬁers using featureCounts version 1.4.5 and
Ensembl version 77 (50 samples), and featureCounts version 1.5.0 and Ensembl
version 83 (15 samples) for the human genes. For the Drosophila gene annotation,
Ensembl version 77 was used for both data sets.
From the data set of 50 samples with different stimulations and combinations
thereof, transcripts per million (TPMs) were calculated for each gene with non-
zero counts in at least one sample. If a gene had at least one zero count, a pseudo-
count of one was added to all samples for this gene. The human gene TPMs were
then normalized by Loess regression on the Drosophila TPMs and then served as
input for the Lasso linear regression.
The data set consisting of 15 samples was normalized to constant numbers of
sample cells by using size factors calculated by “DESeq2” from the Drosophila
counts and applied to the human gene counts as described before59. We then
carried out differential expression analysis using “DESeq2” with the design formula
“CpG+ IL10+Myc+ CpG:IL10.” Genes with a count average smaller than “30”
were discarded.
Regression analysis. Linear regression analysis of GE values from RNA-seq data
(TPMs scaled to standard units) described in Supplementary Table 5 and meta-
bolite measurements (scaled to standard units) was performed within the statistical
framework R using Lasso regression within the ‘glmnet’ package. The Lasso could
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select from coefﬁcients for the individual stimuli and all pairwise combinations of
external stimuli. The Lasso parameter lambda was selected such that it minimized
the cross-validation error. In Supplementary Fig. 1, the Lasso regression coefﬁcients
are shown for the gene models with highest prediction accuracies (R2 > 0.8, 9731
genes). Replicate samples per condition varied (see Supplementary Table 5 for
details).
Sample preparation for metabolic measurements. Cells were counted 24 h after
stimulation and 5 × 106 cells were centrifuged (300 × g, 5 min, 4 °C). Supernatants
were transferred into a new tube, whereas cell pellets were washed two times in
cold phosphate-buffered saline (PBS) and resuspended in ice-cold 80% MeOH.
Supernatants were ﬁltered using 10 kDa Amicon® ultra centrifugal ﬁlters (Merck,
Darmstadt, Germany) and centrifuged for 30 min, 4000 × g, at 4 °C. Metabolites
from pellets were extracted using 80% methanol64. In brief, cell pellets were vor-
texed in 80% MeOH and centrifuged (10,000 × g, 6 min, 4 °C). The supernatant was
removed and the cell pellet was washed two more times with 80% MeOH. All
supernatants were combined and dried for 2 h in a vacuum evaporator. Gln
metabolism was investigated by stable isotope tracing. P493-6 MYChigh and
MYClow cells were washed once in warm PBS and seeded in Gln-free medium
supplemented with 2 mM uniformly labeled 13C5-Gln, 1-13C-Gln, or ɑ-15N Gln.
MYClow cells were stimulated with IL10, CpG, and IL10+ CpG, respectively, as
described before. Achievement of isotopic steady state was conﬁrmed and no
signiﬁcant changes in isotope enrichment in the organic acids analysed were
observed between 18 and 30 h of stimulation. Subsequently, all isotope tracing
experiments were performed for 24 h.
Metabolic analysis. A 600MHz Avance III spectrometer (BrukerBioSpin,
Rheinstetten, Germany) was used to acquire one-dimensional (1D) 1H and two-
dimensional (2D) 1H–13C heteronuclear single-quantum correlation spectra as
published before61. Absolute concentrations from 1D and 2D nuclear magnetic
resonance (NMR) data were calculated employing individual peak calibration
factors and MetaboQuant58. Amino acids, tryptophan metabolites, and inter-
mediates of the methionine and polyamine metabolism were determined by mass
spectrometry (MS) as previously described60,62,63. For each metabolite, a stable
isotope labelled internal standard was used.
Organic acids of the TCA cycle were analysed by high performance liquid
chromatography (HPLC)–electrospray ionization (ESI)–tandem MS (MS/MS)
employing an API 4000 QTrap mass spectrometer (ABSciex, Darmstadt, Germany)
hyphenated to a 1200 SL HPLC (Agilent, Boeblingen, Germany). Negative mode
ionization and multiple reaction monitoring with a transition for each isotopolog
was performed. A Discovery HS F5-3 HPLC column (2.1 × 150 mm, 3 μm; Supelco,
Bellefonte, PA, USA) with a Security Guard column (C18, Phenomenex,
Aschaffenburg, Germany) and gradient elution with 0.1% formic acid in water (v/
v) as mobile phase A and acetonitrile as mobile phase B was used.
For the measurement of amino acids and organic acids from stable isotope
tracer experiments, the said methods were extended to cover the transitions of all
expected isotopologs.
In addition to HPLC–MS/MS analysis, intracellular citrate was also analysed by
gas chromatography (GC)–MS after derivatization. A 50 µL aliquot of the sample
extract was dried followed by methoximation and silylation and subsequent
GC–MS analysis employing the derivatization protocol and instrumental setup
previously described60. An injection volume of 1 µL and splitless injection was
used.
Nucleobases were analysed by HPLC–quad time of ﬂight–MS after hydrolysis of
nucleic acids. The pellet obtained after metabolite extraction described above was
hydrolyzed with 200 µL 2M HCl at 120 °C for 4 h. After hydrolysis, 1 M NaOH was
used to neutralize the solution. The neutralized solution was then dried with a
vacuum evaporator and the residue was re-solved in 100 μL of water for liquid
chromatography–MS analysis. A Maxis Impact QTOF-MS (Bruker Daltonics,
Bremen, Germany) hyphenated to an Thermo Scientiﬁc Dionex Ultimate 3000
UHPLC system (Idstein, Germany) through an ESI source operated in positive ion
mode was used. Separation was carried out on a Waters Atlantis T3 reversed-phase
column (2.1 × 150 mm, 3 µm) with mobile phase A (0.1 % formic acid in H2O, v/v)
and B (0.1% formic acid in acetonitrile, v/v) and gradient elution. The column was
kept at 35 °C and a ﬂow rate of 0.3 mL/min was employed.
MS data were acquired in a mass range of 50–1000 m/z with an acquisition rate
of 2 spectra/s. Mass calibration was performed using sodium formate clusters (10
mM sodium formate in 50:50 (v/v) water/ isopropanol). For data analysis, the peak
area of the [M+H]+ peak of each possible isotopolog was integrated.
Correction for natural stable isotope abundance and tracer impurity in the
tracing experiments was performed using an in-house tool to correct MS/MS data
and IsoCor for full-MS data65.
GOT2 activity assay. GOT2 activity was measured by an indirect colorimetrical
and a direct NMR based method66,67. For colorimetrical analysis, 200 µL of soni-
ﬁcated cell lysate was incubated with 1 mL 2mM α-KG/200 mM aspartate in 0.1 M
phosphate buffer (pH 7.4) at 40 °C. After 60 min, 1 mL of the 2,4-dini-
trophenylhydrazine (1 mM, solved in 1 N HCl) was added. After 20 min at room
temperature (RT), 10 mL of 0.4 N sodium hydroxide were added. At the end of
exactly 30 min, the optical density of the solution was measured at 505 nm, using
water as the blank. As controls 200 µL of each lysate without incubation at 40 °C
was mixed with 2,4-dinitrophenylhydrazine. For calibration, a Pyr standard curve
was used.
For NMR-based analysis, cells were soniﬁcated in isotonic HEPES buffer (25
mM HEPES, 1 mM NaH2PO4, 106 mM NaCl2, 19 mM KCl, 1 mM CaCl2). Thirty
microliters of cell lysates were mixed with 970 µL of 5 mM glutamate, 5 mM OAA,
and 200 µM pyridoxal-5’-phosphate in isotonic HEPES buffer. Samples were
incubated for indicated time points at 37 °C. Afterwards, enzyme activity was
stopped by cooking at 99 °C for 7 min. The samples were frozen at – 80 °C,
measured as descriped above and Asp and α-KG were quantiﬁed from 1D 1 H
NMR spectra employing the Chenomx software suite (Chenomx, Inc., Edmonton,
Canada).
Analysis of respiration and glycolytic capacities. OCR and ECAR rates were
measured by means of an XF Analyzer (Seahorse Bioscience, North Billerica, MA,
USA). Before seeding, cell culture plates were coated with Cell Tak (Corning, Inc.,
Corning, NY, USA) according to the manufacturer’s instructions. Metabolites and
inhibitors were added to ports and measurements were performed. P493-6 MYClow
cells were stimulated for 24 h in medium supplemented with 11 mM Glc and/or 2
mM Gln. Unstimulated MYChigh cells were grown in the same medium in parallel.
The next day, cells were counted and 100,000 cells per well were seeded in XF Base
medium (supplemented with 11 mM Glc and/or 2 mM Gln) according to manu-
facturer’s protocol for suspension cells. After attachment to the surface cells were
incubated for 30 min at 37 °C without the addition of CO2 to equilibrate to mea-
surement conditions. In the meantime corresponding inhibitors as indicated in the
ﬁgures legends were prepared and loaded into the ports of a hydrated assay car-
tridge. Port loading and concentrations used are described in Supplementary
Tables 8-10. Assay cartridge was calibrated, cell plate loaded into XF analyzer and
cycles were performed as listed in Supplementary Table 11. From these data, basal
parameters were calculated according to manufactures protocol (difference Port A
to Port D). OCR dependency was calculated as followed:
OCR dependency ð%Þ ¼ 100 ðOCRBaseline  OCRInhibitor
OCRBaseline
´ 100Þ
Immunoblot analysis. Western blot analysis was performed using 10% SDS
polyacrylamide gels and polyvinylidene diﬂuoride blotting membranes (Merck). To
analyse knockdown efﬁciencies, the following antibodies were used: rabbit α-GOT1
(14886-1-AP, Proteintech, Rosemont, IL, USA), rabbit α-GOT2 (14800-1-AP,
Proteintech), rabbit α-STAT3 (9132, Cell Signaling Technology, Danvers, MA,
USA), rabbit α-p65 (4764, Cell Signaling Technology), and mouse α-GAPDH
(ab8245, Abcam, Cambridge, UK). For visualization of the bound antibodies,
secondary horseradish peroxidase-coupled antibodies from Santa Cruz Bio-
technology (Dallas, TX, USA) were employed (sc-2004 and sc-2005). Uncropped
versions of all blots can be found at the end of the Supplementary Information
(Supplementary Fig. 13-19).
Immunohistochemical analysis of GOT2. A total of 137 B-cell lymphoma spe-
cimens were obtained from the ﬁles of the Kiel Lymph Node Registry according to
ethical approval. All the lymphomas were classiﬁed according to the World Health
Organization classiﬁcation using standard histologic, immunohistochemical, and
molecular criteria. All lymphomas were analyzed using tissue microarrays (TMAs)
containing two cores of 1 mm or 0.6 mm (for the Molecular Mechanisms in
Malignant Lymphoma Network specimens) for each case. Specimens were scored
as negative (no staining of lymphoma cells), partially positive (< 50% of lymphoma
cells), and positive (> 50% of lymphma cells are positive), respectively. Immuno-
histochemical staining was performed on TMAs using a rabbit α-GOT2 (14800-1-
AP, Proteintech) at a dilution of 1:100 and using antigen retrieval citrate mbuffer
pH 6.0. The corresponding secondary antibody was purchased from Medac
(Wedel, Germany).
Proteomic analysis. The samples (three replicates, 50 µg each) were subjected to
tryptic digestion using the GASP-protocol. Quantitative label-free proteomic
analysis was accomplished by nano-HPLC-SWATH-MS. A TOP40 method was
used for the library runs and variable SWATH-windows (60 windows from 400 to
1000 m/z) were used for SWATH-MS-runs. Data were normalized on cell count
and statistical evaluation was done using the IBM SPSS Statistics 23 using analysis
of variance and the Bonferroni post hoc test. Data were corrected for multiple
testing according to Benjamini and Hochberg.
Chromatin immunoprecipitation. ChIP analysis of STAT3 and p65 was per-
formed as described before12. Brieﬂy, cells were stimulated with IL10, CpG, or IL10
+ CpG for 1 h at 37 °C. Cells were washed with PBS and crosslinked with 2 mM
disuccinimidyl glutarate in PBS for 45 min at RT. Secondary crosslinking was
performed with 1% formaldehyde for 15 min at RT. The reaction was stopped by
the addition of 0.1 M glycine for 10 min at RT. Cells were washed twice and lysed
in 50 mM Tris-HCl pH 8.0, 2 mM EDTA, 1% Igepal, and 10% glycerol for 15 min
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03803-x
12 NATURE COMMUNICATIONS |  (2018) 9:1514 | DOI: 10.1038/s41467-018-03803-x | www.nature.com/naturecommunications
on ice. Nuclear pellets were resuspended in 50 mM Tris-HCl pH 8.1, 1% SDS, and
10 mM EDTA, and sonicated by means of a Bioruptor (Diagenode, Seraing, Bel-
gium). One percent Triton X-100 was added to the sheared chromatin and debris
were removed by centrifugation. For one IP, 50 μL of protein A-coupled magnetic
beads (Life Technologies) were incubated with 5 µg of a-IgG (sc-2027, Santa Cruz
Biotechnology), a-STAT3 (sc-482, Santa Cruz Biotechnology), or a-p65 (sc-372,
Santa CruzBiotechnology) overnight at 4 °C. After washing, sheared chromatin was
added overnight at 4 °C. Beads were washed with RIPA-buffer (50 mM HEPES-
KOH pH7.6, 500 mM LiCl, 1 mM EDTA, 1% Igepal, and 0.7% sodium deox-
ycholate) and once with 1M Tris-HCl pH 8.0, 0.5 M EDTA. Ten percent Chelex
(Bio Rad Laboratories, Hercules, CA, USA) were added to the washed beads and
heated for 10 min at 95 °C. Protein was digested by using Proteinase K (30 min, 65 °
C) and afterwards inactivated by heating to 95 °C for 10 min. The GOT2 locus was
ampliﬁed by real-time PCR using the following primer pair: fwd: 5′-TCG CTG
TGA CGT GGC TC-3′, rev: 5′-TGA AGG TAA GGA CAG GGA CTT C-3′.
Statistical analysis. Except for the Cox and regression models, statistical analysis
was performed using GraphPad Prism 6. Standard normal distribution was
assumed for all samples and equal variances were tested using the Brown–Forsythe
test. Differences between groups were assumed to be statistically signiﬁcant in all
experiments for p-values < 0.05.
The Cox proportional hazards model was calculated using the R package
‘survival’ on the R-CHOP-treated DLBCL patients18. Activated B-cell like (ABC)
and germinal center B-cell like (GCB) classiﬁed patients were included, while
unclassiﬁed patients were excluded. In addition to the molecular DLBCL subtype,
the IPI was included as a binary variable (1 if IPI > 2, 0 otherwise), age was
included as a continuous variable, and GOT2 expression was included as a binary
variable (1 if GOT2 expression > median, 0 otherwise).
Data availability. RNA sequence data that support the ﬁndings of this study have
been deposited in the BioProject database of the NCBI with the accession numbers
PRJNA312050 (https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA312050;)
and PRJNA356698 (https://www.ncbi.nlm.nih.gov/bioproject/?
term=PRJNA356698). Proteomic data are available within the supplementary
information as exel ﬁle. All other data of this study are available from the corre-
sponding author upon reasonable request.
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